Hansoh Pharma
Hansoh Pharmaceutical Group Company Limited, commonly known as Hansoh Pharma, is a leading biopharmaceutical enterprise headquartered in China. Established in 1995, the company has made significant strides in the pharmaceutical industry, focusing on the research, development, manufacturing, and marketing of innovative medicines. With a strong presence in major operational regions across Asia and beyond, Hansoh Pharma is dedicated to addressing unmet medical needs. The company’s core business areas include oncology, central nervous system disorders, and autoimmune diseases, with a portfolio of unique products that leverage advanced biopharmaceutical technologies. Notably, Hansoh Pharma has achieved recognition for its commitment to quality and innovation, positioning itself as a key player in the global market. With numerous accolades and a robust pipeline of therapies, Hansoh Pharma continues to contribute to the advancement of healthcare solutions.
DitchCarbon Score
How does Hansoh Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hansoh Pharma's score of 0 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hansoh Pharma's reported carbon emissions
In 2021, Hansoh Pharma reported total carbon emissions of approximately 122,328,000 kg CO2e. This figure includes about 6,256,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and approximately 116,072,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Currently, there are no publicly disclosed reduction targets or climate pledges from Hansoh Pharma, indicating a potential area for future commitment in addressing climate change. The absence of specific initiatives or targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, Hansoh Pharma's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | |
|---|---|
| Scope 1 | 6,256,000 |
| Scope 2 | 116,072,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hansoh Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
